Recent Research Analysts’ Ratings Updates for Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals (NASDAQ: JAZZ) has recently received a number of price target changes and ratings updates:

• 11/22/2024 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
• 11/21/2024 – Jazz Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $163.00 price target on the stock, down previously from $166.00.
• 11/21/2024 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
• 11/18/2024 – Jazz Pharmaceuticals had its price target raised by analysts at Robert W. Baird from $154.00 to $162.00. They now have an “outperform” rating on the stock.
• 11/7/2024 – Jazz Pharmaceuticals had its price target lowered by analysts at TD Cowen from $200.00 to $195.00. They now have a “buy” rating on the stock.
• 11/7/2024 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
• 10/23/2024 – Jazz Pharmaceuticals had its price target raised by analysts at Royal Bank of Canada from $175.00 to $179.00. They now have an “outperform” rating on the stock.

Jazz Pharmaceuticals Trading Up 0.9 %

JAZZ traded up $1.14 during trading on Wednesday, hitting $122.78. The company’s stock had a trading volume of 131,701 shares, compared to its average volume of 671,435. The firm’s 50 day moving average price is $115.38 and its 200-day moving average price is $111.29. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $7.42 billion, a PE ratio of 17.29, a PEG ratio of 1.03 and a beta of 0.57. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. This represents a 0.23 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the company’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,110 shares of company stock worth $720,160 in the last ninety days. Insiders own 4.20% of the company’s stock.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. CWA Asset Management Group LLC purchased a new stake in Jazz Pharmaceuticals during the 3rd quarter worth $3,197,000. Swedbank AB purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter worth $106,936,000. Pacer Advisors Inc. boosted its position in Jazz Pharmaceuticals by 15.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after purchasing an additional 278,465 shares during the period. Philip James Wealth Mangement LLC purchased a new stake in Jazz Pharmaceuticals during the 3rd quarter worth $830,000. Finally, Victory Capital Management Inc. boosted its position in Jazz Pharmaceuticals by 42.7% in the 2nd quarter. Victory Capital Management Inc. now owns 205,492 shares of the specialty pharmaceutical company’s stock valued at $21,932,000 after buying an additional 61,458 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.